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Abstract
Background: Gitelman syndrome (GS) is an autosomal recessive renal tubular disorder characterised by renal salt
wasting with hypokalaemia, metabolic alkalosis, hypomagnesaemia and hypocalciuria. It is caused by mutations in
SLC12A3 encoding the sodium-chloride cotransporter on the apical membrane of the distal convoluted tubule. We
report a South African family with five affected individuals presenting with hypokalaemia and unusual food cravings.
Methods: The affected individuals and two unaffected first degree relatives were enrolled into the study. Phenotypes
were evaluated through history, physical examination and biochemical analysis of blood and urine. Mutation screening
was performed by sequencing of SLC12A3, and determining the allele frequencies of the sequence variants found in
this family in 117 ethnically matched controls.
Results: The index patient, her sister, father and two aunts had a history of severe salt cravings, fatigue and tetanic
episodes, leading to consumption of large quantities of salt and vinegar. All affected individuals demonstrated
hypokalaemia with renal potassium wasting. Genetic analysis revealed that the pseudo-dominant pattern of
inheritance was due to compound heterozygosity with two novel mutations: a S546G substitution in exon 13,
and insertion of AGCCCC at c.1930 in exon 16. These variants were present in the five affected individuals, but
only one variant each in the unaffected family members. Neither variant was found in any of the controls.
Conclusions: The diagnosis of GS was established in five members of a South African family through clinical
assessment, biochemical analysis and mutation screening of the SLC12A3 gene, which identified two novel
putative pathogenic mutations.
Keywords: South Africa, Gitelman syndrome, Hypokalaemia, Tubular disorders, Salt craving, Mutation, Pseudo-dominant
inheritance
Background
Gitelman syndrome (GS) is an autosomal recessive renal
tubular disorder which is characterised by renal salt
wasting with hypokalaemia, metabolic alkalosis, hypo-
magnesaemia and hypocalciuria [1]. It is caused by mu-
tations in the solute carrier family 12, member 3 gene
(SLC12A3) encoding the sodium-chloride cotransporter
(NCC) of the distal convoluted tubule (DCT) [2–4]. Al-
though a proportion of patients with GS have homozygous
mutations, the majority are compound heterozygotes, with
a different mutation on each allele [5]. It is therefore not
uncommon to encounter affected cases in successive gen-
erations of the same family [6, 7], giving rise to a pseudo-
dominant pattern of inheritance [7, 8].
GS usually presents during adolescence or adulthood,
although it may be completely asymptomatic for life.
Common symptoms include cramps or tetany, paraes-
thesias, lethargy, muscle weakness [2] and, rarely, peri-
odic paralysis [9]. Polydipsia and nocturia commonly
occur, as well as cravings for salty substances [10–13].
Uncommonly, patients may have growth retardation, de-
layed puberty [14], cardiac dysrhythmias or sudden
cardiac death [15–17]. Diabetes mellitus and chronic
kidney disease have been reported with higher
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frequencies in GS than in the general population [8]. A
large amount of phenotype variability occurs, with poor
correlation between specific mutations and clinical man-
ifestations [18, 19]. Moreover, features such as hypokal-
aemia and hypomagnesaemia may change throughout
the course of one individual’s life. Differences in dietary
habits or gender [20] may contribute to phenotype vari-
ability, but in most cases the reasons are unknown.
The diagnosis of GS is based on the typical symptoms
and biochemical abnormalities. It is distinguished from
Bartter syndrome (BS) by a low rate of calcium excretion
(urine calcium/creatinine ratio ≤0.1 mmol/mmol for GS
versus >0.1 mmol/mmol for BS) [10, 21, 22]. Genetic
analysis is a valuable tool in assisting with the diagnosis
of GS, but is available only at specialised centres [23].
In this paper we describe the clinical, biochemical and
genetic features of a South African family with GS. The
family is interesting in that several individuals across
two generations were affected, the affected individuals
reported unusual food cravings, and two novel putative
pathogenic mutations were identified.
Methods
Clinical assessment
The index patient was referred to our nephrology clinic
at Tygerberg Hospital (Cape Town, South Africa) with
the problem of persistent hypokalaemia. She gave a his-
tory of several family members with similar symptoms.
These individuals, along with the index patient’s un-
affected mother and brother, agreed to be studied to as-
sist with the diagnosis of a suspected renal tubular
disorder. The index patient, her sister and father were
examined at our clinic at the start of the study. They
were then followed up along with the other study par-
ticipants (except for the father, who had passed away in
the interim) at their local general practitioners’ offices.
Special emphasis was placed on obtaining a detailed
history of drug use, previous and current symptoms as-
sociated with GS, as well as the presence and nature of
food cravings.
The index patient (study participant A, proband, see
Fig. 1) was a white Afrikaner female from the Northern
Cape province in South Africa. She was 31 years old at
the commencement of the study. Her lowest recorded
serum potassium level had been 2.4 mmol/L 8 years
earlier. She had experienced symptoms of marked salt
craving, weakness, fatigue and tetany. This presentation,
along with a positive family history, led us to consider
the diagnosis of GS.
She gave the history of a predilection for salt-
containing and sour foods since childhood. She had de-
veloped the habit of drinking white vinegar with extra
salt added. Initially she consumed half a glass of vinegar
with a heaped teaspoon of salt per day, but this escalated
to the point where she was drinking up to two litres of
this mixture per week. More peculiarly, she would pre-
pare ice cubes of the same mixture for later consump-
tion. This practice was also followed by her younger
sister (participant B). It emerged that her father (F) and
his older sisters (D and E) had done the same when they
were young, also drinking white vinegar mixed with salt.
The index patient reported that she had learnt the habit
from her father and aunts. They all had a fondness for
sour foods, including lemons and sour figs, often with
extra salt added. During their childhood, sour-tasting
berries and plants were sometimes gathered and con-
sumed. However, at the time of our study, most of the
participants had outgrown these cravings. One affected
individual had grown to dislike salt and sour foods and
avoided them altogether.
Only the index patient (participant A) had previously
had significant polydipsia, consuming up to seven litres
of water a day. All five affected participants had experi-
enced episodes of paraesthesiae, especially of the lips
and hands, often culminating in overt tetany with carpo-
pedal spasm. This was often provoked by anxiety accom-
panied by mild hyperventilation. Other notable
symptoms reported were nausea and vomiting, fatigue,
cramps, palpitations, atypical chest pain, muscular weak-
ness and syncopal attacks (Table 1).
Fig. 1 Pedigree of the extended South African family with Gitelman syndrome. Affected participants are represented by shaded symbols; the
proband is indicated by an arrow; deceased individuals are shown with a cross inside the symbol
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All participants but one were heavy smokers and two
had a history of ischaemic heart disease. Both unaffected
participants had previously been diagnosed with hyper-
tension and one affected participant had high blood
pressure recorded for the first time during this study.
The index patient’s paternal grandfather had died sud-
denly at age 36, after collapsing at work without any
prior history of illness. He was presumed to have died
from a myocardial infarction, but the exact cause of
death was never established.
All affected female participants in our study had had
one or more successful pregnancies, albeit with generally
severe gestational nausea and vomiting. The only poor
outcome reported was that of the index patient’s first
pregnancy which ended in foetal death due to abruptio
placentae at 35 weeks’ gestation. One participant experi-
enced worsening of her food cravings during pregnancy,
whereas the others reported improvement in their
symptoms.
Biochemical analysis of blood and urine
Analysis of blood and urine samples from the first three
participants was done at the National Health Laboratory
Service at Tygerberg Hospital. The remaining partici-
pants’ samples were analysed at PathCare laboratories.
These laboratories also provided the results of previous
tests done on the study participants.
Genetic analysis
Genomic DNA was isolated from whole blood samples
at the Faculty of Medicine and Health Sciences of Stel-
lenbosch University according to established methods.
Genetic screening of all 26 exons of the SLC12A3 gene
was performed in accordance with protocols described
by Simon et al. [3].
Following the identification of two sequence variants
in exons 13 and 16 of SLC12A3, the respective allele fre-
quencies were determined in 117 ethnically matched
controls by means of high-resolution melt (HRM) ana-
lysis on a RotorGene 6000 analyser (Corbett Life Sci-
ence). The anonymised controls were recruited from the
Western Province Blood Transfusion Service clinics in
Cape Town. Samples with altered heat denaturation pro-
files following HRM analysis were Sanger sequenced in
order to characterise the sequence variants.
Results
Biochemical analysis of blood and urine
The results of various biochemical analyses are provided
in Table 2. Amongst the five participants suspected to
have GS, four were found to be hypokalaemic. The fifth
had had hypokalaemia documented previously, and was
taking potassium supplementation at the time of testing
for the study. The four hypokalaemic participants all had
inappropriately high renal potassium excretion, with
urinary K+:Cr ratios >1.5 mmol/mmol. Four of the five
affected participants had hypocalciuria, with urinary cal-
cium:creatinine ratios <0.1 mmol/mmol, as would be ex-
pected with GS. All participants had normal serum
magnesium levels.
The affected participants had elevated serum bicar-
bonate levels, with normal blood pH values, and in four
of them the urine pH was >6.0. All affected participants
had varying degrees of renal function impairment, two
with an estimated glomerular filtration rate (eGFR)
below 60 ml/min/1.73 m2. All affected participants ex-
cept one (whose blood pressure was elevated at the time
of testing) had elevated renin activity, but normal serum
aldosterone levels and normal aldosterone:renin ratios.
Genetic analysis
Genetic analysis of the affected participants identified
several sequence variants in the SLC12A3 gene (Fig. 2).
All five affected individuals were found to harbour
compound heterozygous putative mutations consisting
of an AGC>GGC missense variant in exon 13 (exon
13+69A>G; p.S546G; ss2137143999) and an insertion
of six bases (AGCCCC) in exon 16 (c.1930insAGCCCC;
ss2137144000). These two heterozygous sequence vari-
ants, when compounded, would be expected to alter the
protein structure and could thus be implicated in loss
of function of the NCC. Unaffected participant G was
found to be heterozygous for the S546G variant with-
out the presence of an additional variant. Similarly,
unaffected participant C possessed only the heterozy-
gous c.1930insAGCCCC variant.
Neither of these variants are found in the ExAC data-
base (http://exac.broadinstitute.org/), and, to our know-
ledge, have not been described previously. The
frequencies of the p.S546G and c.1930insAGCCCC vari-
ants were determined in unrelated, ethnically matched
controls. Neither variant was observed in any of the 117
controls (234 chromosomes) screened.
Sequence analysis also identified additional variants in
the proband, including a previously described single nu-
cleotide polymorphism (SNP) in exon 6 in the heterozy-
gous state (rs1529927; p.A264G), and three intronic
SNPs, namely homozygous IVS14-8T>C, heterozygous
IVS24-13T>C and heterozygous IVS25+13C>T.
Discussion
Our clinical suspicion of GS in five members of a South
African family has been confirmed. We have charac-
terised the phenotype of these individuals through care-
ful clinical evaluation and biochemical analysis of blood
and urine. We have also characterised their genotype,
identifying compound heterozygosity due to two novel
mutations in the SLC12A3 gene in each of the affected
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individuals. This was responsible for the pseudo-
dominant pattern of inheritance observed in this family.
The striking cravings for salt and vinegar are likely a
response to the volume depletion induced by renal so-
dium wasting. The intake of such large amounts of vin-
egar is unusual, though, and seldom described in
patients with GS. We have come across one other paper
reporting patients with GS drinking the vinegar from
pickle jars [24].
Although GS is generally considered to be a benign
condition, there have been isolated reports suggesting a
link with sudden cardiac death [15–17]. The proposed
mechanism is thought to be diminished cardiovascular
responsiveness to stress such as strenuous exercise [16].
The family history revealed sudden death at a young age
of the index patient’s paternal grandfather. There is,
however, no indication as to whether he had had symp-
toms of GS, and an exact cause of death was never
established. The index patient’s father (participant F)
also suffered suspected sudden cardiac death after col-
lapse without warning symptoms. He, however, was
65 years old and had a clear history of severe coronary
artery disease.
The index patient’s first pregnancy ended in foetal
death due to abruptio placentae at 35 weeks’ gestation.
Her smoking history may have been a contributory
Table 2 Biochemical analysis of blood and random urine samples
Participants A B D E F C G
Blood Ref ranges/units Affected Affected Affected Affected Affected Unaffected Unaffected
Sodium 136–146 mmol/L 141 143 142 140 146 137 133
Potassium (lowest) 3.5–5.1 mmol/L 2.8 2.6 2.8 2.8 2.9 3.6 4.0
Potassium (latest) 3.5–5.1 mmol/L 3.2 3.0 3.0 3.2 4.1 4.1 4.4
Chloride 101–109 mmol/L 100 100 103 101 103 102 102
Urea 2.8–7.2 mmol/L 5.8 7.7 11.7 9.9 13.5 6.4 6.4
Creatinine 59–104 μmol/L 94 82 86 92 111 88 48
eGFR mL/min/1.73 m2 66a 82a 57 55 62a 98 102
Corrected calcium 2.20–2.65 mmol/L 2.33 2.19 2.40 2.32 2.30 2.26 2.23
Albumin 35–52 g/L 41 42 40 44 43 45 43
Magnesium 0.73–1.06 mmol/L 0.85 0.96 0.83 0.77 0.85 1.00 0.97
Phosphate 0.81–1.45 mmol/L 1.08 0.78 1.00 1.00 0.96 1.32 1.43
Alkaline phosphatase 30–120 IU/L 36 43 70 71 47 52 111
Cortisol am 184–618; pm
<276 nmol/L
291 385 203 204 318 145 125
pH 7.36–7.44 7.37 7.38 7.41 7.35 7.35 7.42 7.39
Bicarbonate 23–27 mmol/L 32.3 30.3 30.0 30.0 31.6 27.0 26.0
Renin 2.7–27.7 ng/L (erect) 46.4 40.3 9.1 41.4 68.3 10.6 Not done
Aldosterone 49–1066 pmol/L 152 146 336 357 231 273 Not done
Aldo:renin ratio <118 pmol/ng 3.3 3.6 36.9 8.6 3.4 25.8 Not done
Urine
FE sodium % 1.8 1.6 0.1 0.8 0.8 0.3 0.1
FE potassium % 17.5 25.5 18.3 53.0 23.3 5.3 3.1
FE chloride % 1.6 2.2 0.5 2.4 1.3 0.5 0.1
FE magnesium % 1.4 2.5 0.7 4.5 3.5 0.9 0.4
K:creat ratio <1.5 mmol/mmol in
hypokalaemia
6.0 9.3 6.4 18.4 8.6 2.5 6.4
Ca:creat ratio mmol/mmol 0.04 0.03 0.07 0.18 0.07 0.23 0.22
Mg:creat ratio mmol/mmol 0.13 0.03 0.07 0.38 0.27 0.10 0.08
Osmolality mOsm/kg 813 888 638 539 1049 968 725
pH 6.0 8.0 7.0 7.5 6.5 5.0 5.0 5.0
Protein:creat ratio <0.2 mg/mg 0.15 0.12 0.12 0.18 0.08 0.09 0.08
eGFR estimated glomerular filtration rate as calculated by the CKD-EPI and aMDRD formulae; FE fractional excretion in %
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factor. Pregnancy outcomes are generally favourable in
patients with GS if adequate electrolyte supplementation
is taken [25].
Clinical examination revealed normotension in the af-
fected participants except for participant D, whose blood
pressure was elevated at the time of examination. Al-
though GS is characterised by normotension during
youth, it does not preclude the development of hyper-
tension during later life. It has even been proposed that
individuals with GS may be predisposed to the develop-
ment of hypertension due to chronic vasoconstriction
brought about by the compensatory hyperreninaemic
state, eventually causing hypertension to supervene once
hypovolaemia is overcome [24]. However, there is lack of
consensus over the degree to which the NCC is involved
in determining blood pressure levels, with evidence for
[26] and against this role [27].
Hypokalaemia had been well documented in all the af-
fected participants, along with evidence of inappropriate
urinary potassium losses. All affected participants had
metabolic alkalosis as well as hypocalciuria. They were
all normomagnesaemic. Although hypomagnesaemia is
common in GS, normal magnesium levels are seen in
20–40% of cases [28, 29] and may indicate a milder
manifestation of the disease [30, 31]. It is possible that
hypomagnesaemia may have been present in our partici-
pants when they were experiencing more pronounced
symptoms, notably the episodes of tetany. Hypomagnes-
aemia is strongly implicated in the pathogenesis of tet-
any in GS [32], although the hypokalaemia and alkalosis
may also be responsible.
All affected participants had some degree of impaired
renal function, with two having eGFR values below
60 ml/min/1.73 m2. These individuals were 74 and
69 years old respectively. The reason for their impaired
renal function was not clear, but one participant had a
history of recurrent urinary tract infections in the years
following childbirth, necessitating pelvic floor surgery.
Fig. 2 Sequence chromatograms of theSLC12A3 gene of the family with Gitelman syndrome, indicating the presence of the two mutations S546G
and c.1930insAGCCCC. The proband is indicated as participant A. Participants B, D, E and F are affected family members, while participants C and
G are clinically unaffected
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She also had a history of NSAID use for chronic lower
back pain caused by a previous sports injury. No partici-
pant reported any history of kidney stones, a common
complication often associated with renal impairment. In
contrast to BS, GS has not been directly associated with
renal impairment [33] although isolated cases have been
reported in the literature [34].
Genetic studies in the proband confirmed the diagno-
sis of GS by demonstrating two novel putative loss-of-
function mutations in the SLC12A3 gene. Both these
mutations were also present in the other affected partici-
pants. The two unaffected participants each had one of
the mutations. This suggests that compound heterozy-
gosity is responsible for the phenotype observed in our
affected cohort, i.e. the two mutations occur on different
alleles. Additional support for the pathogenicity of these
variants is provided by the prediction website Mutation-
Taster (http://www.mutationtaster.org), which predicts
both to be “disease causing” with probability values of
0.99 and 1 for S546G and c.1930insAGCCCC, respect-
ively [35]. Also, the PolyPhen-2 tool, which predicts the
possible impact of an amino acid substitution (http://
genetics.bwh.harvard.edu/pph2/index.shtml), predicts
S546G to be “possibly damaging” with a score of 0.603.
Another intriguing observation was that S546G was
present in both the affected father and the unaffected
mother of the proband. This raises the possibility of con-
sanguinity, although it could not be established within at
least the preceding three generations.
Conclusions
We have made a clinical diagnosis of GS in a South Afri-
can family with chronic hypokalaemia and typical symp-
toms. We have confirmed the diagnosis by genetic
analysis and demonstrated two novel mutations in the
SLC12A3 gene in five affected individuals, and in two
family members not clinically affected who harboured
one mutation each. Several local studies have researched
mutations implicated in other tubulopathies, notably
Liddle syndrome [36–39]. However, this study, to our
knowledge, is the first to characterise a family with GS
in Southern Africa.
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